By bringing life-changing benefits to people with rare diseases and cancers, cell and gene therapies are reshaping the field of medicine. These treatments have recently gained tremendous publicity for meeting long-standing unmet needs and being extremely costly. But high production costs are limiting patient access to cell and gene therapies.
Larger patient groups than with earlier therapies make this a highly dynamic moment for healthcare systems, including payers and regulators. But the question is, will novel treatments act as a “forcing function” to make payers adjust? Or can healthcare evolve to keep up with scientific advancements?
Complicated route for ac...
